Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 16 Show results per page	View Search Criteria \| Help With Results


1.		Phase II/III Randomized Trial of Immunotherapy with MoAb 17-1A Given Before vs After Chemotherapy with FAM (5-FU/ADR/MITO-C) in Patients with Advanced Pancreatic Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				no age specified								FCCC-85719 NCI-V85-0077

Last Modified: 8/1/1999


2.		Phase III Randomized Study of Adjuvant MOAB 17-1A plus 5-FU-Based Chemotherapy vs 5-FU-Based Chemotherapy Alone for Surgically Resected Stage III Adenocarcinoma of the Colon (Summary Last Modified 08/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				GW-157-001 NCI-V96-0836

Last Modified: 1/25/2008 First Published: 5/1/1997


3.		Phase III Randomized Study of Adjuvant Edrecolomab Versus No Adjuvant Therapy After Resection in Patients With Stage II Adenocarcinoma of the Colon

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				CLB-9581 CAN-NCIC-CO14, E-C9581, EORTC-40991, NCCTG-C9581, SWOG-C9581, NCT00002968, C9581, CO14

Last Modified: 5/1/1988


4.		Phase III Randomized Pilot Study of Adjuvant Immunotherapy with Murine Monoclonal Antibody vs No Adjuvant Therapy in Patients with Colon Carcinoma (Summary Last Modified 05/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 to 75								NEDH-85999 NCI-V87-0253

Last Modified: 1/1/1989


5.		Phase I/II Study of Recombinant IL-2 Administered in Conjunction with Antitumor MoAb 17-1A in Patients with Colorectal Cancer Metastatic to the Liver (Summary Last Modified 01/89)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				16 and over				NCI				NCI-88-C-64A NCI-T88-0087N, T88-0087

Last Modified: 2/1/2001


6.		Phase II Study of MOAB 17-1A/GM-CSF for 5-FU-Resistant Metastatic Colorectal Cancer (Summary Last Modified 02/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Other				GWCC-5095 NCI-V95-0686, NCT00002664

Last Modified: 8/1/1997


7.		Phase II Immunotherapy with Monoclonal Antibody 17-1A in Patients with Nonresectable Carcinoma of the Pancreas (Summary Last Modified 08/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				NCI-84-C-231A NCI-T84-0539N, T84-0539


8.		Phase II Immunotherapy with Recombinant Gamma Interferon plus Murine Monoclonal Antibody 17-1A in Patients with Colorectal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				FCCC-86777 NCI-T86-0044D, T86-0044

Last Modified: 9/1/1988


9.		Phase II Immunotherapy with Monoclonal Antibody 17-1A Following Pretreatment with Gamma-Interferon in Patients with Metastatic or Localized Adenocarcinoma of the Exocrine Pancreas (Summary Last Modified 09/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				19 and over				NCI				UNMC-08786 NCI-T86-0050O, T86-0050


10.		Phase II Immunotherapy with Gamma Interferon and 17-1A Monoclonal Antibody in Patients with Metastatic Colon Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				UAB-226 NCI-T86-0088D, T86-0088

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute